Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBodyÂ®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma
This is a non-randomised trial with five experimental arms. Each arm has 2 parts: Part 1 (dose escalation) and Part 2 (expansion). Within each arm, participants can only participate in one part. Experimental Arm 1 is investigating epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Arm 2 is investigating epcoritamab + rituximab and lenalidomide (R2) in people with relapsed/refractory (R/R) follicular lymphoma (FL). Experimental Arm 3 is investigating epcoritamab + rituximab and bendamustine (BR) in people with previously untreated FL. Experimental Arm 4 is investigating epcoritamab + rituximab, cisplatin, cytarabine, and dexamethasone (R-DHAX/C) in people with R/R DLBCL eligible for autologous stem cell transplant (ASCT). Experimental Arm 5 is investigating epcoritamab + gemcitabine and oxaliplatin (GemOx) in people with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity.